Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study

Kacan T., Yildiz C., Kacan S. B., Seker M., Ozer H., Cetin A.

GEBURTSHILFE UND FRAUENHEILKUNDE, cilt.77, sa.1, ss.66-72, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1055/s-0042-115566
  • Dergi Adı: GEBURTSHILFE UND FRAUENHEILKUNDE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.66-72
  • Anahtar Kelimeler: apoptosis, endometriosis, everolimus, ovarian reserve, ENDOTHELIAL GROWTH-FACTOR, MAMMALIAN TARGET, RAPAMYCIN, MANAGEMENT, REGRESSION, APOPTOSIS, WOMEN
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Introduction Mammalian target of rapamycin is a pathway to block apoptosis. Recent studies showed that the activity of mammalian target of rapamycin pathway increases in endometriotic lesions. Aim of the present study was to study the effect of everolimus agent, a rapamycin analog, in an experimental endometriosis model.